Spanish healthcare company Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a manufacturer of plasma-derived medicines, announced on Tuesday that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to develop a treatment for sulfur mustard-induced eye injury.
The treatment uses ocular surface immunoglobulin (OSIG) eye drops to neutralize symptoms caused by the chemical warfare agent.
If successful, the preclinical study could lead to US Food and Drug Administration (FDA) approval for the first medical treatment for sulfur mustard ocular injury.
Grifols is also developing an OSIG treatment for dry eye disease, which is expected to enter clinical trials in 2025.
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date